Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.


Hereditary Prostate Cancer Testing in Practice

March 13th 2018

Improvements in Detecting and Treating Metastatic CRPC

March 13th 2018

Utilizing AR-Targeted Therapies in CRPC

March 13th 2018

Assessing Treatment Response in M0 CRPC

March 13th 2018

Other Emerging Combination Approaches in RCC

March 13th 2018

AR-Targeted Therapies in CRPC

March 13th 2018

Treatment Goals in M0 CRPC

March 13th 2018

CRPC: Goals of Imaging for the Detection of Metastasis

March 13th 2018

Guidelines for Early Detection of Metastasis in CRPC

March 13th 2018

Treatment Challenges in Nonmetastatic CRPC

March 13th 2018

Detecting Newly Diagnosed Metastatic Prostate Cancer

March 13th 2018

Sequencing Therapy With ADT Combinations

March 13th 2018

Newly Diagnosed Metastatic Prostate Cancer Treatment

March 13th 2018

Risk Stratification in Nonmetastatic Prostate Cancer

March 13th 2018

Challenges Associated With ADT for Prostate Cancer

March 13th 2018

Considerations for Initiating ADT in Prostate Cancer

March 13th 2018

Eisai And Merck to Collaborate on Lenvatinib Mesylate

March 9th 2018

Lenvatinib mesylate (Lenvima) will be developed and commercialized in a collaboration between its creator, Japan’s Eisai Co. Ltd, and Merck.

Is Your Practice Ready for New Rules on Hazardous Drug Management

March 3rd 2018

Among community oncology practices, the US Pharmacopeia Convention’s General Chapter draft guidelines have already raised the bar for hazardous drug management and imposed costs for compliance.

Pearls of Wisdom for the Field of NSCLC

March 1st 2018

Sequencing Therapies for ALK-Rearranged NSCLC

March 1st 2018